Repligen Corporation RGEN

RGEN Company Overview

Repligen Corporation (NASDAQ: RGEN) is a U.S.-based life sciences company focused on developing and supplying bioprocessing technologies used in the production of biologic drugs, including monoclonal antibodies, recombinant proteins, gene therapies, and vaccines. The company operates within the biopharmaceutical manufacturing and life sciences tools industries, providing products and integrated systems that support upstream and downstream manufacturing workflows. Its primary revenue drivers include filtration technologies, chromatography products, process analytics, and single-use fluid management systems used by biopharmaceutical manufacturers and contract development and manufacturing organizations (CDMOs).

Repligen’s business evolved from a biotechnology company with therapeutic development interests into a specialized bioprocessing supplier through a series of acquisitions and strategic portfolio expansions. According to publicly available information from SEC filings, investor materials, and major financial publications, the company has increasingly focused on high-growth biologics manufacturing markets where demand is supported by expanding biologic drug pipelines and increased outsourcing of manufacturing activities. Repligen is often positioned as a specialized provider of high-value consumables and process technologies that can be integrated into multiple stages of biologic production workflows.